KR102769529B1 - 임상용 변형된 NK-92 haNK003 세포 - Google Patents

임상용 변형된 NK-92 haNK003 세포 Download PDF

Info

Publication number
KR102769529B1
KR102769529B1 KR1020247001475A KR20247001475A KR102769529B1 KR 102769529 B1 KR102769529 B1 KR 102769529B1 KR 1020247001475 A KR1020247001475 A KR 1020247001475A KR 20247001475 A KR20247001475 A KR 20247001475A KR 102769529 B1 KR102769529 B1 KR 102769529B1
Authority
KR
South Korea
Prior art keywords
cells
hank003
cell
irradiated
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247001475A
Other languages
English (en)
Korean (ko)
Other versions
KR20240010558A (ko
Inventor
한스 클링게만
로렌스 보이셀
패트릭 순-시옹
Original Assignee
이뮤너티바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤너티바이오, 인크. filed Critical 이뮤너티바이오, 인크.
Priority to KR1020257004694A priority Critical patent/KR20250026391A/ko
Publication of KR20240010558A publication Critical patent/KR20240010558A/ko
Application granted granted Critical
Publication of KR102769529B1 publication Critical patent/KR102769529B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247001475A 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포 Active KR102769529B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257004694A KR20250026391A (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762468890P 2017-03-08 2017-03-08
US62/468,890 2017-03-08
KR1020237015931A KR102626748B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포
PCT/US2018/021332 WO2018165291A1 (en) 2017-03-08 2018-03-07 MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237015931A Division KR102626748B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257004694A Division KR20250026391A (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포

Publications (2)

Publication Number Publication Date
KR20240010558A KR20240010558A (ko) 2024-01-23
KR102769529B1 true KR102769529B1 (ko) 2025-02-19

Family

ID=63446373

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020247001475A Active KR102769529B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포
KR1020197028804A Active KR102533061B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포
KR1020257004694A Pending KR20250026391A (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포
KR1020237015931A Active KR102626748B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020197028804A Active KR102533061B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포
KR1020257004694A Pending KR20250026391A (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포
KR1020237015931A Active KR102626748B1 (ko) 2017-03-08 2018-03-07 임상용 변형된 NK-92 haNK003 세포

Country Status (9)

Country Link
US (4) US10801013B2 (enExample)
EP (1) EP3592845A4 (enExample)
JP (4) JP7098648B2 (enExample)
KR (4) KR102769529B1 (enExample)
CN (2) CN110418839B (enExample)
AU (2) AU2018231193B2 (enExample)
CA (1) CA3053252C (enExample)
IL (2) IL268617B2 (enExample)
WO (1) WO2018165291A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110418839B (zh) 2017-03-08 2023-06-09 免疫生物公司 用于临床的修饰的NK-92haNK003细胞
JP7241161B2 (ja) * 2018-08-01 2023-03-16 イミュニティーバイオ、インコーポレイテッド 細胞免疫療法の安定した遺伝子改変のための、ホーミング受容体又はサイトカインとキメラ抗原受容体とを含むクアドリシストロニックシステム
CA3092709A1 (en) 2018-10-31 2020-05-07 Nantkwest, Inc. Elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells
CA3117936A1 (en) * 2018-11-26 2020-06-04 Immunitybio, Inc. Il-2 dependent nk-92 cells with stable fc receptor expression
CN119040363A (zh) * 2019-03-15 2024-11-29 河谷细胞有限公司 重组erIL-15 NK细胞
JP7555392B2 (ja) * 2019-07-26 2024-09-24 ナントクウェスト，インコーポレーテッド 腫瘍溶解のための有効な治療用製剤としての、抗体を予め負荷したｃｄ１６＋ｎｋ－９２細胞
US11992504B2 (en) * 2019-11-20 2024-05-28 Immunitybio, Inc. Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
WO2021116913A1 (en) * 2019-12-09 2021-06-17 Nantkwest, Inc. Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
KR20230152783A (ko) 2020-07-07 2023-11-03 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
US20250262301A1 (en) * 2020-10-26 2025-08-21 Shoreline Biosciences, Inc. Methods of inducing antibody-dependent cellular cytotoxicity (adcc) using modified natural killer (nk) cells
CN114807237A (zh) * 2022-05-12 2022-07-29 广东普罗凯融生物医药科技有限公司 一种过表达CD16a的NK细胞的制备方法及其应用
CN119522365A (zh) * 2022-06-28 2025-02-25 塞勒普尔责任有限公司 用于表征针对细胞疗法的产物的方法
US20250298030A1 (en) * 2024-03-20 2025-09-25 Immunitybio, Inc. Compositions and Methods for NK-92 Cells Expressing Native CD16

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842266A4 (en) * 1995-08-04 1999-07-21 Gen Hospital Corp TRANSGENIC PORK AND PORK CELLS HAVING HLA GENES OF MAN
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
EP1007630B1 (en) 1997-04-30 2006-04-19 Hans Klingemann Natural killer cell lines and methods of use
US8034332B2 (en) * 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
CA2289915A1 (en) * 1997-04-30 1998-11-05 Hans Klingemann Natural killer cell lines and methods of use
WO2006023148A2 (en) 2004-07-10 2006-03-02 Fox Chase Cancer Center Genetically modified human natural killer cell lines
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
EP3273993A4 (en) * 2015-03-27 2018-11-07 Nantkwest, Inc. Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer
JP2018517415A (ja) 2015-06-10 2018-07-05 ナントクエスト インコーポレイテッド がんを処置するための改変ｎｋ−９２細胞
CN110418839B (zh) 2017-03-08 2023-06-09 免疫生物公司 用于临床的修饰的NK-92haNK003细胞

Also Published As

Publication number Publication date
KR20240010558A (ko) 2024-01-23
IL316209A (en) 2024-12-01
CA3053252A1 (en) 2018-09-13
CN110418839A (zh) 2019-11-05
EP3592845A4 (en) 2020-12-30
WO2018165291A1 (en) 2018-09-13
KR102626748B1 (ko) 2024-01-17
US20240010979A1 (en) 2024-01-11
JP2024023513A (ja) 2024-02-21
US20200347351A1 (en) 2020-11-05
JP2022130596A (ja) 2022-09-06
CN110418839B (zh) 2023-06-09
IL268617A (en) 2019-10-31
EP3592845A1 (en) 2020-01-15
IL268617B1 (en) 2024-11-01
AU2021236511A1 (en) 2021-10-28
US10774310B2 (en) 2020-09-15
JP2025038128A (ja) 2025-03-18
JP7098648B2 (ja) 2022-07-11
CA3053252C (en) 2023-02-21
AU2018231193B2 (en) 2021-07-22
US12492377B2 (en) 2025-12-09
KR20190118204A (ko) 2019-10-17
IL268617B2 (en) 2025-03-01
JP7398518B2 (ja) 2023-12-14
AU2021236511B2 (en) 2021-12-16
KR102533061B1 (ko) 2023-05-15
US10801013B2 (en) 2020-10-13
KR20230074281A (ko) 2023-05-26
CN116440293A (zh) 2023-07-18
JP2020511131A (ja) 2020-04-16
US20190300854A1 (en) 2019-10-03
US20180258397A1 (en) 2018-09-13
JP7608580B2 (ja) 2025-01-06
AU2018231193A1 (en) 2019-08-08
US11753625B2 (en) 2023-09-12
KR20250026391A (ko) 2025-02-25

Similar Documents

Publication Publication Date Title
JP7608580B2 (ja) 臨床のための、改変されたＮＫ－９２ ｈａＮＫ００３細胞
AU2016202873B2 (en) DAC HYP compositions and methods
KR102096592B1 (ko) 신규한 crispr 연관 단백질 및 이의 용도
US12410234B2 (en) Compositions and methods for retrieving tumor-related antibodies and antigens
US20220017594A1 (en) Il-2 dependent nk-92 cells with stable fc receptor expression
KR20230158573A (ko) 바이러스 벡터 입자의 효력을 평가하는 방법
CN111450098A (zh) 拉米夫定在延缓衰老中的应用以及制备用于筛选延缓衰老药物的细胞模型
CN107058390A (zh) 一种慢病毒载体、重组慢病毒质粒、病毒及病毒的应用
CN113355288B (zh) 一种治疗covid-19的通用型嵌合抗原受体t细胞的制备方法及应用
CN114616239B (zh) 嵌合抗原受体和其中表达有嵌合抗原受体的t细胞
CN116322793A (zh) 改进的使用科卡尔包膜的t细胞转导用慢病毒载体的生成
CN113710268A (zh) 药物递送组合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601